Literature DB >> 24972045

Systemic therapy in HCC: lessons from brivanib.

David Bolos1, Richard S Finn2.   

Abstract

Entities:  

Keywords:  Angiogenesis; Brivanib; FGFR; Fibroblast Growth Factor; Hepatocellular carcinoma; Sorafenib; VEGFR; Vascular Endothelial Growth Factor Receptor

Mesh：

Substances：

Year:  2014        PMID： 24972045     DOI： 10.1016/j.jhep.2014.06.019

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  12 in total

1.  Identification a novel tumor-suppressive hsa-miR-599 regulates cells proliferation, migration and invasion by targeting oncogenic MYC in hepatocellular carcinoma.

Authors:  Jingjing Tian; Xibao Hu; Wei Gao; Jie Zhang; Ming Chen; Xinrong Zhang; Junhong Ma; Hongxia Yuan
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

2.  CCAT1 promotes hepatocellular carcinoma cell proliferation and invasion.

Authors:  Huaqiang Zhu; Xu Zhou; Hong Chang; Hongguang Li; Fangfeng Liu; Chaoqun Ma; Jun Lu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Hepatocellular Carcinoma: Current Questions and Future Directions.

Authors:  Robert G Gish
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-03

4.  Down-regulated miR-28-5p in human hepatocellular carcinoma correlated with tumor proliferation and migration by targeting insulin-like growth factor-1 (IGF-1).

Authors:  Xiaomin Shi; Fei Teng
Journal:  Mol Cell Biochem       Date:  2015-07-10       Impact factor: 3.396

5.  A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib.

Authors:  A G Duffy; S V Ulahannan; L Cao; O E Rahma; O V Makarova-Rusher; D E Kleiner; S Fioravanti; M Walker; S Carey; Y Yu; A M Venkatesan; B Turkbey; P Choyke; J Trepel; K C Bollen; S M Steinberg; W D Figg; T F Greten
Journal:  United European Gastroenterol J       Date:  2015-10       Impact factor: 4.623

6.  A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma.

Authors:  Chia-Jui Yen; Tae-You Kim; Yin-Hsun Feng; Yee Chao; Deng-Yn Lin; Baek-Yeol Ryoo; Dennis Chin-Lun Huang; David Schnell; Julia Hocke; Arsène-Bienvenu Loembé; Ann-Lii Cheng
Journal:  Liver Cancer       Date:  2018-03-15       Impact factor: 11.740

7.  Improved Survival in Hepatocellular Carcinoma Patients with Cardiac Arrhythmia by Amiodarone Treatment through Autophagy.

Authors:  Sheng-Teng Huang; Wei-Fan Hsu; Hung-Sen Huang; Jia-Hau Yen; Mei-Chen Lin; Cheng-Yuan Peng; Hung-Rong Yen
Journal:  Int J Mol Sci       Date:  2019-08-15       Impact factor: 5.923

Review 8.  Trends and Challenges in Tumor Anti-Angiogenic Therapies.

Authors:  József Jászai; Mirko H H Schmidt
Journal:  Cells       Date:  2019-09-18       Impact factor: 6.600

Review 9.  Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment.

Authors:  Guihong Liu; Tao Chen; Zhenyu Ding; Yang Wang; Yuquan Wei; Xiawei Wei
Journal:  Cell Prolif       Date:  2021-03-02       Impact factor: 6.831

Review 10.  FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.

Authors:  Gentry King; Milind Javle
Journal:  Curr Oncol Rep       Date:  2021-07-16       Impact factor: 5.075
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.